Health

Chairman:  Joe Pitts (PA-16)
Jurisdiction: 
Public health and quarantine; hospital construction; mental health; biomedical research and development; health information technology, privacy, and cybersecurity; public health insurance (Medicare, Medicaid) and private health insurance; medical malpractice and medical malpractice insurance; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.

Members

Republicans

Chairman: Joe Pitts (PA)
Vice Chairman: Michael C. Burgess, M.D. (TX)
Ed Whitfield (KY)
John Shimkus (IL)
Mike Rogers (MI)
Tim Murphy (PA)
Marsha Blackburn (TN)
Phil Gingrey (GA)
Cathy McMorris Rodgers (WA)
Leonard Lance (NJ)
Bill Cassidy (LA)
Brett Guthrie (KY)
Morgan Griffith (VA)
Gus Bilirakis (FL)
Renee Ellmers (NC)
Joe Barton (TX)
Fred Upton (MI)

Democrats

Ranking Member: Frank Pallone, Jr. (NJ)
John D. Dingell (MI)
Eliot L. Engel (NY)
Lois Capps (CA)
Jan Schakowsky (IL)
Jim Matheson (UT)
Gene Green (TX)
G.K. Butterfield (NC)
John Barrow (GA)
Donna M. Christensen (VI)
Kathy Castor (FL)
John Sarbanes (MD)
Henry A. Waxman (CA)

May 16, 2013 | Press Release

WASHINGTON, DC – House Energy and Commerce Committee leaders today continued their examination into reports that Health and Human Services Secretary Kathleen Sebelius may have solicited funding or assistance from the health care industry to help implement the health care law.

>>
May 16, 2013 | Blog Post

WASHINGTON, DC – On the heels of President Obama’s public declarations last Friday that there was no evidence that the massive new health care law is increasing premiums, the Energy and Commerce Committee this week released a report entitled “The Looming Premium Rate Shock.” The report chronicles internal

>>
May 15, 2013 | Press Release

WASHINGTON, DC – The House Committee on Energy and Commerce today advanced legislation to secure America’s prescription drug supply chain and reauthorize two important drug user fee programs for new and generic animal drugs.

>>

Pages